Journal of Clinical Oncology
Early palliative care for patients with terminal non-small-cell lung cancer (NSCLC) improves the timing of final chemotherapy administration and is associated with an earlier transition to hospice care, according to a study published online Dec. 27 in the .
Joseph A. Greer, M.D., of the Massachusetts General Hospital Cancer Center in Boston, and colleagues investigated whether early palliative care affected the frequency and timing of chemotherapy use and hospice care for patients with metastatic NSCLC. This 18-month study involved 151 tertiary care patients with newly diagnosed metastatic NSCLC who were randomized to receive either early palliative care integrated with standard oncology care or standard oncology care alone.
Measures of outcome included the number and types of chemotherapy regimens, and the frequency and timing of chemotherapy administration and hospice referral.
Read the full story at: http://www.physiciansbriefing.com/Article.asp?AID=660207
Source: HealthDay
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More